Core Insights - Andrew Dudum, co-founder of Hims & Hers, has recently joined the billionaire ranks due to the company's impressive financial performance and a lucrative partnership with Novo Nordisk for the sale of the weight loss drug Wegovy [1][2][3] Financial Performance - Hims & Hers reported a Q1 2025 revenue of $586 million, a 111% increase from $278 million in the same period last year [1] - The company's net profit surged from $11.1 million to $49.5 million year-over-year [1] Stock Market Impact - Following the announcement of the partnership with Novo Nordisk, Hims & Hers' stock price increased by 73%, recovering from a previous decline [2] - As of May 7, the company's market capitalization approached $12 billion [1] Partnership Details - Hims & Hers has become one of only three telehealth providers in the U.S. authorized to sell Wegovy, a popular weight loss medication [2] - The collaboration with Novo Nordisk was announced on April 29, 2025, enhancing the company's product offerings [2] Founder Background - Andrew Dudum, a 36-year-old entrepreneur, has seen his net worth rise to $1.1 billion, primarily from his holdings in Hims & Hers [3] - Dudum co-founded Hims & Hers in 2017, focusing initially on male health products before expanding into female health [4] Marketing Strategy - Hims & Hers invests nearly half of its $1.5 billion revenue in marketing, promoting the convenience of online consultations and prescriptions [5][6] - The company positions its weight loss drug Wegovy at a competitive price of $599 per month, significantly lower than the retail price of $1,350 [6]